Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
Significant technological advances in radiotherapy have been made in the past few
decades. High-precision radiotherapy has recently become popular and is contributing to …
decades. High-precision radiotherapy has recently become popular and is contributing to …
Reinvigorating exhausted CD8+ cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy
MA Hossain, G Liu, B Dai, Y Si, Q Yang… - Medicinal Research …, 2021 - Wiley Online Library
Immunotherapy has revolutionized the treatment of cancer in recent years and achieved
overall success and long‐term clinical benefit in patients with a wide variety of cancer types …
overall success and long‐term clinical benefit in patients with a wide variety of cancer types …
Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: impact on prognosis and benefit from adjuvant therapy
A León-Castillo, SM De Boer, ME Powell… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of …
[HTML][HTML] Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1)
C Li, S Zhao, Y Zheng, Y Han, X Chen, Z Cheng… - European journal of …, 2021 - Elsevier
Background To investigate the safety and activity of preoperative pembrolizumab combined
with chemoradiotherapy for resectable oesophageal squamous cell carcinoma …
with chemoradiotherapy for resectable oesophageal squamous cell carcinoma …
[HTML][HTML] Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion
Y Lan, M Moustafa, M Knoll, C Xu, J Furkel… - Cancer cell, 2021 - cell.com
Localized radiotherapy (RT) induces an immunogenic antitumor response that is in part
counterbalanced by activation of immune evasive and tissue remodeling processes, eg, via …
counterbalanced by activation of immune evasive and tissue remodeling processes, eg, via …
[HTML][HTML] Phase II, single-arm trial of preoperative short-course radiotherapy followed by chemotherapy and camrelizumab in locally advanced rectal cancer
Z Lin, M Cai, P Zhang, G Li, T Liu, X Li… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background In locally advanced rectal cancer (LARC), preoperative short-course
radiotherapy (SCRT) with delayed surgery has been shown to be as effective as long-course …
radiotherapy (SCRT) with delayed surgery has been shown to be as effective as long-course …
PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma
N Maekawa, S Konnai, M Nishimura, Y Kagawa… - NPJ precision …, 2021 - nature.com
Immunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1)
represents promising treatments for human cancers. Our previous studies demonstrated PD …
represents promising treatments for human cancers. Our previous studies demonstrated PD …
Sites of metastasis and association with clinical outcome in advanced stage cancer patients treated with immunotherapy
MA Bilen, JM Shabto, DJ Martini, Y Liu, C Lewis… - BMC cancer, 2019 - Springer
Background Selecting the appropriate patients to receive immunotherapy (IO) remains a
challenge due to the lack of optimal biomarkers. The presence of liver metastases has been …
challenge due to the lack of optimal biomarkers. The presence of liver metastases has been …
Personalized ultrafractionated stereotactic adaptive radiotherapy (PULSAR) in preclinical models enhances single-agent immune checkpoint blockade
Purpose Harnessing the immune-stimulatory effects of radiation by combining it with
immunotherapy is a promising new treatment strategy. However, more studies …
immunotherapy is a promising new treatment strategy. However, more studies …
Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells
Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved
outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials. gov: NCT03563716) when …
outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials. gov: NCT03563716) when …